XENETIC BIOSCIENCES INC
XBIONASDAQTrading Snapshot
- Day Range
- $2.28 – $2.32
- 52-Week Range
- $1.87 – $13.93
- Volume
- $2.03B
- Avg Volume
- $1.66B
- Shares Outstanding
- 2.3M
- Next Earnings
- Nov 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $660,601
- P/E Ratio
- -1.9
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-1.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +48.6%
Why Investors Own XBIO
- ✓High-growth profile — revenue up +25.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
XENETIC BIOSCIENCES INC
XBIO
StockOtter · stockotter.spaceAbout XENETIC BIOSCIENCES INC
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
XENETIC BIOSCIENCES INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift XBIO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
XENETIC BIOSCIENCES INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.